Trevi Therapeutics has announced significant milestones in its clinical programs for Haduvio (nalbuphine), an investigational therapy aimed at treating chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). 4 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Singapore’s Agency for Science, Technology and Research (A*STAR) and US biotech incubator Flagship Pioneering have agree to collaborate on advancing health and sustainability outcomes in Singapore and the broader Asia Pacific region. 4 October 2024
The US Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment designed to address the root cause of myotonic dystrophy type 1 (DM1), under development by US biotech Avidity Biosciences . 4 October 2024
Caliway Biopharmaceuticals has successfully completed its initial public offering, raising NT$6.4 billion ($206 million), the largest IPO in Taiwan's biotech industry to date. 3 October 2024
US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer treatments. 3 October 2024
PeptiDream says that its wholly-owned PDRadiopharma subsidiary has entered into a strategic partnership with French nuclear medicines firm Curium. 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
Liquidia Corporation and Pharmosa Biopharm have amended the current exclusive licensing agreement for the development and commercialization of L606. 3 October 2024
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
UK-based biotech LoQus23 Therapeutics has closed a £35 million ($43 million) series A financing round, led by Forbion, with support from SV Health Investors' Dementia Discovery Fund and Novartis Venture Fund. 2 October 2024
Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
Spanish epigenetics firm Oryzon Genomics has announced the receipt of the official meeting minutes from a recent End-of-Phase II meeting for vafidemstat in borderline personality disorder (BPD) with the US Food and Drug Administration (FDA). 2 October 2024
Halda Therapeutics, a US biotech company advancing cancer treatments, announced the appointment of Christian Schade as president and chief executive. 1 October 2024
Californian rare disease company Ultragenyx Pharmaceutical has received a positive reimbursement decision from the UK’s health technology assessor, the National Institute for Health and Care Excellence (NICE). 5 January 2024
Boston, USA-based biotech start-up Kojin Therapeutics has announced the appointment of Harvey Berger as its new chairman, president and chief executive (CEO). 5 January 2024
A significant collaboration agreement has been reached between Belgian biotech Galapagos and private Californian company BridGene Biosciences. 4 January 2024
US pharma company Esperion Therapeutics on Wednesday announced a $125 million deal with Japanese drugmaker Daiichi Sankyo’s European subsidiary (DSE) to resolve Esperion's demand for $300 million from the company over Esperion's cholesterol reduction drugs. 4 January 2024
US clinical-stage biotech start-up QurAlis has announced the opening of its European Union (EU) headquarters in Leiden, the Netherlands. 4 January 2024
French immuno-oncology company Innate Pharma today announced that it has strengthened its leadership and corporate governance with the appointment of two new executive board members. 4 January 2024
Adding to the growing list pf big pharma licensing and M&A deals in the attractive area of antibody-drug conjugate (ADC) drugs, China-headquartered MediLink Therapeutics has entered into a worldwide collaboration and license accord with Swiss pharma giant Roche. 3 January 2024
US clinical-stage immunotherapy specialist ImmunityBio yesterday announced an up to $320 million royalty financing and equity investment in the company by Oberland Capital. 3 January 2024
UK-based Arecor Therapeutics has announced the appointment of Dr Helen Parris as senior vice president, commercial and general manager of Tetris Pharma. 3 January 2024
China and USA-based Allorion Therapeutics has entered into an exclusive option and global license agreement with UK pharma major AstraZeneca. 3 January 2024
Shares of US neurogenetic focused biotech Voyager Therapeutics shot up 30% to $10.86 today, after it announced a capsid license agreement and strategic collaboration with Novartis. 2 January 2024
British and American biotech Apollo Therapeutics has boosted its series C financing round by $33.5 million, bringing the total amount to $260 million. 2 January 2024
South Korean biotech LegoChem Biosciences has entered into a license agreement with Janssen Biotech, to develop and commercialize LCB84. 29 December 2023
US oncology drug developer Oncternal Therapeutics took a 10% initial tumble after it revealed a patient in an early-stage trial of its ONCT-808, but closed the day up 18% at $0.59. 29 December 2023
Shares in US muscle biology specialist Cytokinetics soared 70% to $77.34 this morning, as it announced positive results from the much-awaited SEQUOIA trial of its aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM). 27 December 2023